Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xtant Medical Holdings (XTNT) Short-Term Debt issuances (2016 - 2025)

Xtant Medical Holdings (XTNT) has disclosed Short-Term Debt issuances for 8 consecutive years, with $25.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Short-Term Debt issuances fell 3.7% to $25.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $103.9 million, a 4.85% decrease, with the full-year FY2024 number at $112.6 million, up 44.01% from a year prior.
  • Short-Term Debt issuances was $25.8 million for Q3 2025 at Xtant Medical Holdings, down from $26.7 million in the prior quarter.
  • In the past five years, Short-Term Debt issuances ranged from a high of $30.4 million in Q1 2024 to a low of $10.1 million in Q3 2022.
  • A 5-year average of $20.6 million and a median of $19.8 million in 2023 define the central range for Short-Term Debt issuances.
  • Peak YoY movement for Short-Term Debt issuances: fell 24.73% in 2022, then soared 88.76% in 2023.
  • Xtant Medical Holdings' Short-Term Debt issuances stood at $13.6 million in 2021, then rose by 29.09% to $17.5 million in 2022, then soared by 30.34% to $22.9 million in 2023, then increased by 15.09% to $26.3 million in 2024, then decreased by 2.14% to $25.8 million in 2025.
  • Per Business Quant, the three most recent readings for XTNT's Short-Term Debt issuances are $25.8 million (Q3 2025), $26.7 million (Q2 2025), and $25.2 million (Q1 2025).